BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation, nondeductible expense, other, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's effective income tax rate reconciliation, nondeductible expense, other, amount?
- BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation, nondeductible expense, other, amount of $321.25K in Q4 2025.
- How has BioCryst Pharmaceuticals's effective income tax rate reconciliation, nondeductible expense, other, amount changed year-over-year?
- BioCryst Pharmaceuticals's effective income tax rate reconciliation, nondeductible expense, other, amount increased by 42.9% year-over-year, from $224.75K to $321.25K.
- What is the long-term trend for BioCryst Pharmaceuticals's effective income tax rate reconciliation, nondeductible expense, other, amount?
- Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's effective income tax rate reconciliation, nondeductible expense, other, amount has grown at a 82.0% compound annual growth rate (CAGR), from $388K to $1.29M.